newsfilter
← Latest News
GlobeNewswire·

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

ZNTL
  • Zentalis Pharmaceuticals announced two presentations at the ESMO Congress 2026 in Madrid, Spain, scheduled for October 23-27, 2026.
  • A rapid oral presentation titled "Azenosertib in platinum-resistant ovarian cancer (PROC): overall survival analysis from Part 1b of the DENALI study" is scheduled for Friday, October 23, 2026, from 4:15 p.m. to 5:45 p.m. CEST.
  • The oral presentation (Presentation Number 1242RO) will showcase long-term survival benefits of azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer.
  • A trial-in-progress poster presentation regarding the ASPENOVA Phase 3 study is scheduled for Monday, October 26, 2026, from 12:00 p.m. to 12:45 p.m. CEST (Presentation Number 1339TiP).
  • The DENALI study is a Phase 2 registration-intended trial (NCT05128825) evaluating azenosertib in PROC patients, with Part 2 designed to support accelerated approval pending positive outcomes.
  • Part 2a of DENALI selected 400mg QD 5:2 as the optimal monotherapy dose, while recruitment at the 300mg QD 5:2 dose level was discontinued.
  • Part 2b involves enrollment expansion to approximately 100 patients at the 400mg QD 5:2 dose and is currently enrolling.
  • Part 2c aims to broaden the study population to include approximately 40 patients previously treated with a taxane-containing regimen and is currently enrolling.
  • The ASPENOVA Phase 3 trial is designed to enroll approximately 420 patients to compare azenosertib monotherapy (400mg QD 5:2) against standard-of-care single-agent chemotherapy for full approval.
  • The primary endpoint for ASPENOVA is progression-free survival, with key secondary endpoints including overall survival and overall response rate.
  • Azenosertib is an investigational first-in-class WEE1 inhibitor targeting Cyclin E1-positive platinum-resistant ovarian cancer, a biomarker-selected population comprising approximately 50% of PROC patients.
  • There is currently no approved treatment option specifically for the Cyclin E1-positive platinum-resistant ovarian cancer population.